Systemic interferon-alpha treatment for idiopathic Sweet's syndrome.
Despite the various therapeutic strategies used in the treatment of acute febrile neutrophilic dermatoses, interferon-alpha has so far been proposed only as an intralesional monotherapy for cutaneous lesions and has only had partial success. We now describe the treatment of a long-standing, previously drug resistant, case of idiopathic Sweet's syndrome. After an initial successful combined short therapy with systemic interferon-alpha and hydroxyurea, the results were maintained by long-term treatment with interferon-alpha only. To our knowledge, this is the first report showing a clear response to the drug in a patient affected by Sweet's syndrome.
Bianchi
L
L
Department of Dermatology, Tor Vergata University of Rome, Italy. Luca.Bianchi@uniroma2.it
Masi
M
M
Hagman
J H
JH
Piemonte
P
P
Orlandi
A
A
D000328:Adult; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use*; D016463:Sweet Syndrome / Q000188:drug therapy* / Q000473:pathology
D007155:Immunologic Factors; D016898:Interferon-alpha; D006918:Hydroxyurea